Silence Therapeutics (NASDAQ:SLN) Reaches New 1-Year High – Should You Buy?

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) hit a new 52-week high on Friday . The stock traded as high as $11.19 and last traded at $11.1750, with a volume of 28903 shares trading hands. The stock had previously closed at $10.92.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SLN. Cantor Fitzgerald started coverage on Silence Therapeutics in a report on Wednesday, June 24th. They set an “overweight” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a report on Wednesday, June 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Silence Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.00.

Silence Therapeutics Price Performance

The stock has a market cap of $495.97 million, a P/E ratio of -6.60 and a beta of 1.38. The firm’s fifty day moving average price is $7.89 and its two-hundred day moving average price is $6.59.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.14). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 105.34%. The business had revenue of $0.42 million for the quarter, compared to the consensus estimate of $1.25 million. On average, research analysts expect that Silence Therapeutics PLC Sponsored ADR will post -0.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC increased its position in shares of Silence Therapeutics by 18.1% in the second quarter. GAMMA Investing LLC now owns 11,063 shares of the company’s stock valued at $121,000 after acquiring an additional 1,698 shares during the period. Seven Fleet Capital Management LP grew its stake in shares of Silence Therapeutics by 6.2% in the first quarter. Seven Fleet Capital Management LP now owns 156,759 shares of the company’s stock worth $826,000 after purchasing an additional 9,159 shares during the last quarter. Bank of America Corp DE increased its holdings in Silence Therapeutics by 903.8% during the 1st quarter. Bank of America Corp DE now owns 29,773 shares of the company’s stock valued at $157,000 after purchasing an additional 26,807 shares during the period. ADAR1 Capital Management LLC increased its holdings in Silence Therapeutics by 628.2% during the 1st quarter. ADAR1 Capital Management LLC now owns 172,157 shares of the company’s stock valued at $907,000 after purchasing an additional 148,514 shares during the period. Finally, SG Americas Securities LLC raised its position in Silence Therapeutics by 11.8% during the 1st quarter. SG Americas Securities LLC now owns 286,698 shares of the company’s stock valued at $1,511,000 after purchasing an additional 30,358 shares during the last quarter. Institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.